Belite Bio logo

Belite Bio

BLTE | NASDAQ
Chart Builder DCF Calculator
$162.56
-$1.79 (-1.09%)
At close: Nov 16, 2026, 4:00 PM ET
$163.00
+$0.44 (+0.27%)
After-hours: Nov 16, 2026, 4:30 PM ET
-1.09%

Rating

Updated: Nov 16, 2026
22.9
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #969/1021 (Top 95%)

Key Statistics

Market Data

Market Cap $6.55B
1D Range
161.51 166.50
52W Range
109.18 193.61

Valuation (TTM)

PE -56.84
PB 8.43
EV/EBITDA -50.58

Valuation (NTM)

Forward PE 81.06
Forward PEG -1.45
Price Target $239.50
Loading financial charts...

Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular de...

Sector Healthcare
Industry Biotechnology
Employees 41
IPO Date Apr 29, 2022
Fiscal Year January - December

Latest News

What Belite Bio (BLTE) Said on Its Q3 Earnings Call

4 days ago · marketbeat.com

What Belite Bio (BLTE) Said on Its Q3 Earnings Call
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update

4 days ago · globenewswire.com

Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results

12 days ago · globenewswire.com

Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

1 month ago · globenewswire.com

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

2 months ago · globenewswire.com

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

2 months ago · zacks.com

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

2 months ago · globenewswire.com

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Why Is Belite Bio Stock Soaring Friday?

2 months ago · benzinga.com

Why Is Belite Bio Stock Soaring Friday?

Earnings

Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$237.50
Upside
+46.10%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.